内大麻素系统
单酰甘油脂肪酶
阿那达胺
脂肪酸酰胺水解酶
神经科学
大麻素受体
医学
神经影像学
心理学
内科学
受体
兴奋剂
作者
Alex J. Berry,Olga Zubko,Suzanne Reeves,Robert Howard
出处
期刊:Brain Research
[Elsevier BV]
日期:2020-09-25
卷期号:1749: 147135-147135
被引量:40
标识
DOI:10.1016/j.brainres.2020.147135
摘要
Studies investigating alterations of the endocannabinoid system (ECS) in Alzheimer's disease (AD) in humans have reported inconsistent findings so far. We performed a systematic review of studies examining alterations of the ECS specifically within humans with AD or mild cognitive impairment (MCI), including neuroimaging studies, studies of serum and cerebrospinal fluid biomarkers, and post-mortem studies. We attempted to identify reported changes in the expression and activity of: cannabinoid receptors 1 and 2; anandamide (AEA); 2-arachidonoylglycerol (2-AG); monoacylglycerol lipase (MAGL); fatty acid amide hydrolase (FAAH); and transient receptor potential cation channel V1 (TRPV1). Twenty-two studies were identified for inclusion. Mixed findings were reported for most aspects of the ECS in AD, making it difficult to identify a particular profile of ECS alterations characterising AD. The included studies tended to be small, methodologically heterogeneous, and frequently did not control for important potential confounders, such as pathological progression of AD. Eight studies correlated ECS alterations with neuropsychometric performance measures, though studies infrequently examined behavioural and neuropsychiatric correlates. PROSPERO database identifier: CRD42018096249.
科研通智能强力驱动
Strongly Powered by AbleSci AI